Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8(+) T cells

A. Hanoteau, C. Henin, D. Svec, C. Bisilliat Donnet, S. Denanglaire, D. Colau, P. Romero, O. Leo, B. Van den Eynde, M. Moser,

. 2017 ; 6 (8) : e1318234. [pub] 20170511

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031948

An important question is how chemotherapy may (re-)activate tumor-specific immunity. In this study, we provide a phenotypic, functional and genomic analysis of tumor-specific CD8(+) T cells in tumor (P815)-bearing mice, treated or not with cyclophosphamide. Our data show that chemotherapy favors the development of effector-type lymphocytes in tumor bed, characterized by higher KLRG-1 expression, lower PD-1 expression and increased cytotoxicity. This suggests re-engagement of T lymphocytes into the effector program. IFN-I appears involved in this remodeling. Our findings provide some insight into how cyclophosphamide regulates the amplitude and quality of tumor-specific immune responses.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031948
003      
CZ-PrNML
005      
20171101105610.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1080/2162402X.2017.1318234 $2 doi
035    __
$a (PubMed)28919989
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hanoteau, Aurélie $u Department of Molecular Biology, ULB Cancer Research Center, Université Libre de Bruxelles, Gosselies, Belgium.
245    10
$a Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8(+) T cells / $c A. Hanoteau, C. Henin, D. Svec, C. Bisilliat Donnet, S. Denanglaire, D. Colau, P. Romero, O. Leo, B. Van den Eynde, M. Moser,
520    9_
$a An important question is how chemotherapy may (re-)activate tumor-specific immunity. In this study, we provide a phenotypic, functional and genomic analysis of tumor-specific CD8(+) T cells in tumor (P815)-bearing mice, treated or not with cyclophosphamide. Our data show that chemotherapy favors the development of effector-type lymphocytes in tumor bed, characterized by higher KLRG-1 expression, lower PD-1 expression and increased cytotoxicity. This suggests re-engagement of T lymphocytes into the effector program. IFN-I appears involved in this remodeling. Our findings provide some insight into how cyclophosphamide regulates the amplitude and quality of tumor-specific immune responses.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Henin, Coralie $u Department of Molecular Biology, ULB Cancer Research Center, Université Libre de Bruxelles, Gosselies, Belgium.
700    1_
$a Svec, David $u Institute of Biotechnology, Academy of Science of the Czech Republic, Prague, Czech Republic.
700    1_
$a Bisilliat Donnet, Charlotte $u Department of Molecular Biology, ULB Cancer Research Center, Université Libre de Bruxelles, Gosselies, Belgium.
700    1_
$a Denanglaire, Sébastien $u Department of Molecular Biology, ULB Cancer Research Center, Université Libre de Bruxelles, Gosselies, Belgium.
700    1_
$a Colau, Didier $u Ludwig Institute for Cancer Research of the Université Catholique de Louvain, Brussels, Belgium.
700    1_
$a Romero, Pedro $u Ludwig Institute for Cancer Research of the University of Lausanne, Epalinges, Switzerland.
700    1_
$a Leo, Oberdan $u Department of Molecular Biology, ULB Cancer Research Center, Université Libre de Bruxelles, Gosselies, Belgium.
700    1_
$a Van den Eynde, Benoit $u Ludwig Institute for Cancer Research of the Université Catholique de Louvain, Brussels, Belgium.
700    1_
$a Moser, Muriel $u Department of Molecular Biology, ULB Cancer Research Center, Université Libre de Bruxelles, Gosselies, Belgium.
773    0_
$w MED00190079 $t Oncoimmunology $x 2162-4011 $g Roč. 6, č. 8 (2017), s. e1318234
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28919989 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171101105701 $b ABA008
999    __
$a ind $b bmc $g 1255541 $s 992975
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 6 $c 8 $d e1318234 $e 20170511 $i 2162-4011 $m Oncoimmunology $n Oncoimmunology $x MED00190079
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace